Products
Micvotabart Biosimilar Monoclonal Antibody (Fibronectin EDB) for Research
Cat No.: GMP-Bios-INN-1283
Anti-FN extracellular domain B therapeutic antibody (Pre-made Micvotabart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Micvotabart (development code PYX-201) is a monoclonal antibody-drug conjugate targeting fibronectin (FN1). It is developed by Pyxis Oncology and Pfizer for solid tumors. It is in Phase I/II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1283-1mg | 1mg | 3090 |
| GMP-Bios-INN-1283-10mg | 10mg | |
| GMP-Bios-INN-1283-100mg | 100mg | |
| GMP-Bios-INN-1283-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Micvotabart biosimilar, Whole mAb, Anti-FN extracellular domain B Antibody: Anti-Fibronectin/FN1/FN/Cold-insoluble globulin (CIG) therapeutic antibody |
| INN Name | Micvotabart |
| Target | FN extracellular domain B |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | 7ah1:AA |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | 2024 |
| Companies | Pyxis Oncology;Pfizer |
| Conditions Approved | na |
| Conditions Active | Solid tumours |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
